Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The corneal collagen and associated stromal protein matrix is the primary structural component of the eye's cornea, accounting for approximately 90% of its total thickness [1]. It is composed of highly organized collagen fibrils, predominantly Type I and Type V, which are arranged in parallel lamellae to provide mechanical strength and maintain corneal shape [1, 3]. These fibrils are precisely spaced by small leucine-rich proteoglycans (SLRPs), such as lumican and keratocan, which are essential for maintaining the optical transparency required for vision [3]. In pathological conditions like keratoconus or post-surgical ectasia, the structural integrity of this matrix is compromised, leading to progressive thinning and visual distortion [2, 4]. This matrix is the direct therapeutic target of corneal collagen cross-linking (CXL), a procedure that uses riboflavin as a photosensitizer under UV-A light to induce new covalent bonds between collagen molecules [2]. This intervention increases the biomechanical stiffness of the stroma, effectively halting the progression of ectatic diseases and preserving visual acuity [2]. (Citations: [1] Meek & Knupp, Prog Retin Eye Res, 2015; [2] Raiskup & Spoerl, Ocul Surf, 2013; [3] Hassell & Birk, Exp Eye Res, 2010; [4] NIH/NEI Keratoconus Overview).
Photo-induced oxidative cross-linking of collagen fibers to enhance biomechanical stability
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Corneal collagen and associated stromal protein matrix.